Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.
Background: Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definiti...
| Publicado en: | Quality of Life Research Vol. 23; no. 5; pp. 1411 - 1420 |
|---|---|
| Autores principales: | , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Jun2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103824737&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 103824737 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09629343 GPQ jtl: Quality of Life Research issn: 09629343 maglogo: N pubinfo: dt: Jun2014 vid: 23 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 103824737 NLM24395525 2012593873 10.1007/s11136-013-0608-1 NLM24395525 PMC4032617 103824737 ppf: 1411 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach. aug: au: Andrei, Adin-Cristian Grady, Kathleen L affil: Bluhm Carrdiovascular Institute, Northwestern University, 676 N St Clair St., Suite 1700, Chicago, IL, USA, aandrei@nmh.org. sug: subj: Heart Failure Psychosocial Factors Kaplan-Meier Estimator Quality of Life Quality-Adjusted Life Years Cardiotonic Agents Therapeutic Use Prospective Studies Dose-Response Relationship, Drug Double-Blind Studies Female Heart Failure Diagnosis Heart Failure Drug Therapy Heart Failure Mortality Human Male Middle Age Questionnaires Quinolines Therapeutic Use Sickness Impact Profile Statistics Treatment Outcomes Ventricular Function, Left Drug Effects Middle Aged: 45-64 years Female Male ab: Background: Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.Methods: To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as quality-adjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT- and PHYS-adjusted OS.Results: In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT- and PHYS-adjusted OS compared to the placebo arm.Conclusions: We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|